AUS
NZ
UK
CA
USA
IND
Highlights
- Radiopharm Theranostics (RAD) secures ethics approval for a Phase 1 cancer trial.
- The trial targets HER2-positive cancers using the novel 177Lu-RAD202 therapy.
- Lutetium-177 isotope aims to deliver localized radiation with minimal side effects.
Radiopharm Theranostics (ASX:RAD) has received approval from the Bellberry Human Research Ethics Committee to initiate the Phase 1 clinical trial of its innovative cancer therapy, 177Lu-RAD202. This marks a significant milestone in advancing therapies targeting HER2-positive cancers. The approval enables the submission of the trial protocol to the Therapeutic Goods Administration (TGA), a crucial step in the Australian regulatory process.
Therapeutic Innovation with Radiopharmaceuticals
Radiopharmaceuticals are a cutting-edge approach that combines radioactive isotopes with targeted delivery mechanisms to diagnose or treat diseases. Radiopharm’s 177Lu-RAD202 therapy uses Lutetium-177, a radionuclide with a short half-life, combined with a targeting antibody designed to bind specifically to HER2 protein receptors. These receptors are commonly overexpressed in certain cancers, such as breast and gastric cancers.
The localized radiation emitted by Lutetium-177 aims to disrupt tumor growth while minimizing damage to surrounding healthy tissues. This precision-focused approach positions radiopharmaceuticals as a promising avenue for addressing treatment gaps in oncology.
The HEAT Trial Overview
The clinical trial, named HEAT (HER2 Antibody Therapy with Lutetium-177), will be conducted across multiple sites in Australia. As an open-label, dose-escalation study, it will evaluate the safety, tolerability, and preliminary clinical activity of the therapy in patients with solid tumors. This first-in-human "basket" trial will target multiple cancer types rather than a single indication.
Early research on a similar compound, 99mTc-labeled RAD202, demonstrated favorable safety profiles and biodistribution, providing a strong foundation for further studies. Preclinical data also indicated tumor growth inhibition and improved survival rates in HER2-positive cancer models.
Addressing Unmet Needs in Oncology
Radiopharm Theranostics is committed to developing innovative solutions for challenging cancer types. The trial aims to provide new hope for patients who have not responded to existing treatments or cannot tolerate current therapies.
CEO Riccardo Canevari noted that the 177Lu-RAD202 therapy represents an opportunity to address significant treatment gaps for HER2-positive metastatic cancer patients. With its unique design, the therapy has the potential to reshape outcomes for patients with limited options.
Radiopharm’s pioneering approach underscores its leadership in the radiopharmaceutical space, bringing advanced cancer therapies closer to clinical application.
